reported HL >25 dB at 8 kHz in 70% of 199 patients 11 years after CBCT. 6- 8, 11- 13 Analyzing audiograms, Glendenning et al. The reported incidence of ototoxicity in TCSs varies greatly depending on diagnostic criteria and the cumulative dose of cisplatin. 4, 6- 10 However, longitudinal studies which also consider age-related HL (ARHL) are lacking. 4- 6 This is described in multiple cross-sectional studies after pediatric- and adult-onset cancer and most often documented in testicular cancer survivors (TCSs). ![]() 1- 3 CBCT has considerable toxic side effects including ototoxicity with high-frequency HL. It is a cornerstone in the treatment of patients with testicular cancer (TC) in Norway, resulting in 15-year relative survival rates exceeding 98%. Level of EvidenceĬisplatin-based chemotherapy (CBCT) is widely used for treatment of several malignancies, including head and neck cancers. Specificity for detecting ototoxicity with self-reported questionnaires decreases with extended follow-up. Age-and sex-matching is strongly advised in long-term follow-up of CBCT-related ototoxicity. Importantly, with extended follow-up, hearing thresholds of patients approach those of the general population, possibly due to a less-than-additive effect with age-related hearing loss (ARHL) in CBCT-treated patients. ConclusionĬBCT-related ototoxicity causes high-frequency HL, but in contrast to reports from follow-up studies from the first post-treatment decade, no major progression was found beyond the first post-treatment decade for frequencies 0.125–8 kHz. At S1, age-adjusted HL was identified in all (seven) TCSs reporting decreased hearing whereas at S3, hearing thresholds did not differ from controls in seven out of 20 patients reporting HL. Self-reported HL increased from seven (9%) at S1 to 20 (26%) at S3. In TCSs aged >40 years at first survey, HL at the subsequent survey equaled that of controls. Resultsīetween the two surveys, the prevalence of high-frequency HL (4, 6, and 8 kHz) increased from 73% to 94% but approached those of the aging general population after age adjustment. Hearing loss was defined as thresholds >20 dB at any frequency. ![]() Hearing thresholds were age-adjusted based on age-matched hearing thresholds from the general population (controls). Study DesignĮighty-two TCSs treated with CBCT between 19 in Norway participated in two surveys (S1/S3), including pure-tone audiograms (0.125–8 kHz) and self-reported HL, 12 and 31 years after treatment, respectively. This controlled longitudinal study with extended follow-up investigates HL in testicular cancer survivors (TCSs) after cisplatin-based chemotherapy (CBCT). Cisplatin-related hearing loss (HL) is claimed to progress after treatment.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |